このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Mangalam Drugs & Organics 将来の成長

Future 基準チェック /06

現在、 Mangalam Drugs & Organicsの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長	17.6%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues Are Not Doing Enough For Some Investors

Aug 13

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

May 23

Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding

Mar 28

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business

Feb 07

Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Oct 20

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Mar 29

These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively

May 31

A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Apr 06

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt

Jan 03

Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly

May 23

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Jan 04

Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?

Nov 12

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Sep 20

Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?

Aug 05

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt

Jul 01

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Mangalam Drugs & Organics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

NSEI:MANGALAM - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2024	3,674	-91	N/A	N/A	N/A
12/31/2023	3,595	-170	N/A	N/A	N/A
9/30/2023	3,245	-171	N/A	N/A	N/A
6/30/2023	3,477	-113	N/A	N/A	N/A
3/31/2023	3,702	13	116	395	N/A
12/31/2022	4,109	123	N/A	N/A	N/A
9/30/2022	4,426	159	44	279	N/A
6/30/2022	4,505	182	N/A	N/A	N/A
3/31/2022	4,509	197	-20	257	N/A
12/31/2021	4,185	151	N/A	N/A	N/A
9/30/2021	4,058	175	-73	315	N/A
6/30/2021	3,813	241	N/A	N/A	N/A
3/31/2021	3,800	280	-39	275	N/A
12/31/2020	3,774	309	N/A	N/A	N/A
9/30/2020	3,507	261	221	361	N/A
6/30/2020	3,210	158	N/A	N/A	N/A
3/31/2020	2,824	83	236	305	N/A
12/31/2019	2,423	-28	N/A	N/A	N/A
9/30/2019	2,290	-89	N/A	N/A	N/A
6/30/2019	2,336	-80	N/A	N/A	N/A
3/31/2019	2,276	-80	124	217	N/A
12/31/2018	2,467	10	N/A	N/A	N/A
9/30/2018	2,720	114	N/A	N/A	N/A
6/30/2018	2,833	164	N/A	N/A	N/A
3/31/2018	2,794	199	86	246	N/A
12/31/2017	2,904	247	N/A	N/A	N/A
9/30/2017	2,983	248	N/A	N/A	N/A
6/30/2017	3,044	233	N/A	N/A	N/A
3/31/2017	3,029	223	N/A	428	N/A
12/31/2016	2,906	227	N/A	N/A	N/A
9/30/2016	2,943	203	N/A	N/A	N/A
6/30/2016	2,919	181	N/A	N/A	N/A
3/31/2016	2,952	160	N/A	218	N/A
12/31/2015	3,001	140	N/A	N/A	N/A
9/30/2015	2,807	110	N/A	N/A	N/A
6/30/2015	2,516	101	N/A	N/A	N/A
3/31/2015	2,207	61	N/A	140	N/A
12/31/2014	1,783	65	N/A	N/A	N/A
9/30/2014	1,556	56	N/A	N/A	N/A
6/30/2014	1,425	26	N/A	N/A	N/A
3/31/2014	1,227	-30	N/A	75	N/A
12/31/2013	1,320	-60	N/A	N/A	N/A
9/30/2013	1,293	-84	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MANGALAMの予測収益成長が貯蓄率 ( 6.7% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: MANGALAMの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: MANGALAMの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: MANGALAMの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: MANGALAMの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MANGALAMの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Mangalam Drugs & Organics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues Are Not Doing Enough For Some Investors

Mangalam Drugs & Organics Limited to Report Q1, 2025 Results on Aug 13, 2024

Mangalam Drugs & Organics Limited to Report Q1, 2025 Results on Aug 13, 2024

Mangalam Drugs & Organics Limited Appoints Ms. Anuradha Pandey as Company Secretary, Compliance Officer and Key Managerial Personnel

New major risk - Financial position

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Mangalam Drugs & Organics Limited, Annual General Meeting, May 21, 2024

Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding

Now 22% undervalued

Third quarter 2024 earnings released: EPS: ₹0.31 (vs ₹0.27 in 3Q 2023)

Now 24% undervalued

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business

Second quarter 2024 earnings released: ₹2.26 loss per share (vs ₹1.41 profit in 2Q 2023)

Now 24% undervalued after recent price drop

Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Mangalam Drugs & Organics Limited to Report Q2, 2024 Results on Nov 14, 2023

Now 20% undervalued after recent price drop

First quarter 2024 earnings released: ₹6.02 loss per share (vs ₹1.92 profit in 1Q 2023)

Mangalam Drugs & Organics Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings released: EPS: ₹0.80 (vs ₹12.42 in FY 2022)

Mangalam Drugs & Organics Limited to Report Q4, 2023 Results on May 30, 2023

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Third quarter 2023 earnings released: EPS: ₹0.27 (vs ₹2.54 in 3Q 2022)

Mangalam Drugs & Organics Limited to Report Q3, 2023 Results on Feb 13, 2023

Second quarter 2023 earnings released: EPS: ₹1.41 (vs ₹2.86 in 2Q 2022)

Second quarter 2023 earnings released: EPS: ₹1.41 (vs ₹2.86 in 2Q 2022)

Mangalam Drugs & Organics Limited to Report Q2, 2023 Results on Nov 11, 2022

Mangalam Drugs & Organics Limited, Annual General Meeting, Sep 28, 2022

First quarter 2023 earnings released: EPS: ₹1.92 (vs ₹2.79 in 1Q 2022)

Mangalam Drugs & Organics Limited to Report Q1, 2023 Results on Aug 05, 2022

Chairman & MD recently sold ₹1.3m worth of stock

Investor sentiment improved over the past week

These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively

Full year 2022 earnings released: EPS: ₹12.42 (vs ₹17.67 in FY 2021)

Mangalam Drugs & Organics Limited to Report Q4, 2022 Final Results on May 26, 2022

Investor sentiment improved over the past week

A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Mangalam Drugs & Organics Limited Announces Executive Changes

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt

Investor sentiment improved over the past week

Insufficient new directors

Insufficient new directors

First quarter 2022 earnings released: EPS ₹2.79 (vs ₹6.13 in 1Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly

Full year 2021 earnings released: EPS ₹17.67 (vs ₹5.21 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹112

Third quarter 2021 earnings released: EPS ₹4.07 (vs ₹1.04 in 3Q 2020)

Mangalam Drugs & Organics Limited to Report Q3, 2021 Results on Feb 11, 2021

New 90-day low: ₹127

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Mangalam Drugs & Organics Limited Announces Resignation of Prashant J. Pandit as Independent Director

New 90-day low: ₹129

Mangalam Drugs & Organics Limited Announces Change in Directorate

New 90-day high: ₹169

Second quarter 2021 earnings released: EPS ₹7.00

Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

New 90-day high - ₹90.80

Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?

Mangalam Drugs & Organics Limited to Report Q1, 2021 Results on Aug 10, 2020

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt

Mangalam Drugs & Organics Limited to Report Q4, 2020 Results on Jun 29, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘